Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline

On Thursday, Novartis AG (NYSE:NVS) raised its mid-term sales guidance, increasing its compound annual growth rate (CAGR) target to 6% from 5% for 2023-2028.

The upgrade reflects performance from current growth drivers and anticipated launches, many of which are expected to retain U.S. exclusivity into the 2030s.

The updated forecast, announced ahead of the company's Meet Novartis Management event in London, underscores its confidence in sustained momentum.

Novartis has outlined its projections for 2024-2029, maintaining a 5% CAGR target with 2024 as the base year.

The company remains on track to achieve a core operating income margin of over 40% by 2027, supported by continued sales growth and productivity enhancements.

Also Read: Positive Outlook For Novartis As Company ...

Full story available on Benzinga.com